Arbutus Biopharma Corp

ABUS

$5.13

+0.10%

2026-09-04 10:28:37 EDT+$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus ...

C-Suite Executives

(0)

The C-suite executives form a cohesive leadership team driving the company's financial strategy and innovation.

Key Team Members

No executives available for this level

Founder / CEO

C-Level

Board

Director / Board

Other

Key Executives

Name	Title	Compensation	Year Born	Status
Lindsay Androski	President, Chief Executive Officer & Chairman	USD 736,559	1977	Active
Tuan Nguyen	Chief Financial Officer	USD 651,897	1976	Active
Andrew J. Sung	General Counsel	—	—	Active
R. Hector Mackay-Dunn	Corporate Secretary	—	1951	Active

Executive Compensation

(deduped by latest filing date per person-year)

Filing Date	Year	Name	Position	Level	Salary	Bonus	Stock Award	Option Award	Incentive	Other	Total
2026-04-14	2025	Michael McElhaugh	Former Former Interim President President and Chief Chief Executive Officer	Founder / CEO	$109.66K	$0	$582.33K	$1.86M	$0	$1.03M	$3.58M
2026-04-14	2025	Tuan Nguyen	Chief Chief Financial Officer	C-Level	$359.85K	$0	$0	$1.88M	$159.76K	$17.50K	$2.42M
2026-04-14	2025	David C. Hastings	Former Former Chief Chief Financial Officer	C-Level	$138.61K	$0	$296.43K	$944.27K	$0	$839.05K	$2.22M
2026-04-14	2025	Lindsay Androski	President President and Chief Chief Executive Officer	Founder / CEO	$437.75K	$0	$0	$714.75K	$216.51K	$0	$1.37M
2026-04-14	2024	Michael McElhaugh	Former Former Interim President President and Chief Chief Executive Officer	Founder / CEO	$642.50K	$0	$297.12K	$921.46K	$231.75K	$17.25K	$2.11M
2026-04-14	2024	David C. Hastings	Former Former Chief Chief Financial Officer	C-Level	$502.00K	$0	$270.00K	$837.52K	$200.80K	$15.52K	$1.83M

Total Compensation Trend

Sum of disclosed compensation by year (USD million)

Key Roles Compensation Lines

Top founder/C-level executives over time (USD million)

Supply Chain of ABUS

RELATIONS

Upstream

Genevant Sciences Ltd.Third-Party CDMOs (Drug Substance & Drug Product Manufacturing)X-Chem Inc.Proteros biostructures GmbHLipid Excipient Manufacturers (CordenPharma, Merck KGaA, etc.)Oligonucleotide Raw Material Suppliers

Downstream

Moderna, Inc.NASDAQ:MRNA Alnylam Pharmaceuticals, Inc.NASDAQ:ALNY Barinthus Biotherapeutics plcNASDAQ:BRNS Roivant Sciences Ltd.NASDAQ:ROIVAcuitas Therapeutics Inc.Qilu Pharmaceutical Co., Ltd.Gritstone bio, Inc. (fka Gritstone Oncology)

Proxies

Alnylam Pharmaceuticals, Inc.NASDAQ:ALNY Moderna, Inc.NASDAQ:MRNA Roivant Sciences Ltd.NASDAQ:ROIV Barinthus Biotherapeutics plcNASDAQ:BRNS Gilead Sciences, Inc.NASDAQ:GILD

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer